Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels.

@article{Bido2011AmantadineAL,
  title={Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels.},
  author={Simone Bido and Matteo Marti and Michele Morari},
  journal={Journal of neurochemistry},
  year={2011},
  volume={118 6},
  pages={
          1043-55
        }
}
Amantadine is the only drug marketed for treating levodopa-induced dyskinesia. However, its impact on basal ganglia circuitry in the dyskinetic brain, particularly on the activity of striatofugal pathways, has not been evaluated. We therefore used dual probe microdialysis to investigate the effect of amantadine on behavioral and neurochemical changes in the globus pallidus and substantia nigra reticulata of 6-hydroxydopamine hemi-lesioned dyskinetic mice and rats. Levodopa evoked abnormal… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 23 CITATIONS

Effects of a combination treatment of KD5040 and L-dopa in a mouse model of Parkinson’s disease

  • BMC Complementary and Alternative Medicine
  • 2017
VIEW 2 EXCERPTS
CITES BACKGROUND

Similar Papers